4 posts in this category
FDA: “many of the adverse events reported for compounded versions appear to be consistent with adverse events for the FDA‑approved products.”
We’ve all been hearing about the shortage of tirzepatide or semaglutide, but what is a shortage? How does it impact compounding?
The FDA has ended the shortage for tirzepatide, essential copy compounding ends on Feb 18 and March 19
OFA vs FDA Case Join report Nov 21
